Filtered By:
Therapy: Chemotherapy
This page shows you your search results in order of relevance. This is page number 17.
Order by Relevance | Date
Total 74347 results found since Jan 2013.
Multiscale modeling of tumor response to vascular endothelial growth factor (VEGF) inhibitor
In Silico Biol. 2020;14(3-4):71-88. doi: 10.3233/ISB-210235.ABSTRACTVascular endothelial growth factor (VEGF) has been known as a key mediator of angiogenesis in cancer. Bevacizumab is anti-VEGF monoclonal antibody that has been approved by the FDA as a first-line treatment in many types of cancer. In this paper, we extend a previously validated multiscale tumor model to comprehensively include the multiple roles of VEGF during the course of angiogenesis and its binding mechanism with bevacizumab. We use the model to simulate tumor system response under various bevacizumab concentrations, both in stand-alone treatment and ...
Source: In Silico Biol - January 10, 2022 Category: Biology Authors: Melisa Hendrata Janti Sudiono Source Type: research
Cancers, Vol. 14, Pages 884: Inducing Biomechanical Heterogeneity in Brain Tumor Modeling by MR Elastography: Effects on Tumor Growth, Vascular Density and Delivery of Therapeutics
In conclusion, incorporating elastography data results in a more accurate calculation of intratumoral mechanical stresses and enables a better mathematical description of subsequent events, such as the heterogeneous development of the tumor vasculature and intrapatient variations in tumor perfusion and delivery of drugs.
Source: Cancers - February 10, 2022 Category: Cancer & Oncology Authors: Constantinos Harkos Siri Fl øgstad Svensson Kyrre E. Emblem Triantafyllos Stylianopoulos Tags: Article Source Type: research
Multiscale modeling of tumor response to vascular endothelial growth factor (VEGF) inhibitor
In Silico Biol. 2020;14(3-4):71-88. doi: 10.3233/ISB-210235.ABSTRACTVascular endothelial growth factor (VEGF) has been known as a key mediator of angiogenesis in cancer. Bevacizumab is anti-VEGF monoclonal antibody that has been approved by the FDA as a first-line treatment in many types of cancer. In this paper, we extend a previously validated multiscale tumor model to comprehensively include the multiple roles of VEGF during the course of angiogenesis and its binding mechanism with bevacizumab. We use the model to simulate tumor system response under various bevacizumab concentrations, both in stand-alone treatment and ...
Source: In Silico Biol - January 10, 2022 Category: Biology Authors: Melisa Hendrata Janti Sudiono Source Type: research
